Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.

Shin HS, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Baatarkhuu O, Ahn SH.

J Gastroenterol Hepatol. 2012 Sep;27(9):1528-34. doi: 10.1111/j.1440-1746.2012.07145.x.

PMID:
22497450
2.

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.

Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H.

Clin Mol Hepatol. 2014 Sep;20(3):267-73. doi: 10.3350/cmh.2014.20.3.267. Epub 2014 Sep 25.

3.

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.

Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.

Hepatology. 2009 Oct;50(4):1064-71. doi: 10.1002/hep.23145.

PMID:
19637288
4.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

PMID:
20659226
5.

Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.

Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH.

World J Gastroenterol. 2015 Aug 28;21(32):9598-606. doi: 10.3748/wjg.v21.i32.9598.

6.

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.

Kim HJ, Park SK, Yang HJ, Jung YS, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Choi KY.

Clin Mol Hepatol. 2016 Sep;22(3):350-358. Epub 2016 Sep 25.

7.

Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.

Ye XG, Su QM.

World J Gastroenterol. 2013 Oct 21;19(39):6665-78. doi: 10.3748/wjg.v19.i39.6665. Review.

8.

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.

Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F.

Eur J Gastroenterol Hepatol. 2014 Feb;26(2):146-54. doi: 10.1097/MEG.0b013e328365c3e5.

PMID:
24025974
9.
10.

Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.

Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, Suh DJ.

J Gastroenterol Hepatol. 2011 Sep;26(9):1380-8. doi: 10.1111/j.1440-1746.2011.06776.x.

PMID:
21884247
11.

Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.

Kang SH, Yim HJ, Kim HR, Kang K, Suh SJ, Lee HJ, Yoon EL, Kim JH, Seo YS, Yeon JE, Byun KS.

J Clin Gastroenterol. 2014 Nov-Dec;48(10):889-95. doi: 10.1097/MCG.0000000000000066.

PMID:
24440937
12.

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients.

Hwang JA, Kim KB, Yang MJ, Lim SG, Hwang JC, Cheong JY, Cho SW, Kim SS.

Clin Mol Hepatol. 2015 Jun;21(2):131-40. doi: 10.3350/cmh.2015.21.2.131. Epub 2015 Jun 26.

13.

Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B.

Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS.

World J Gastroenterol. 2013 Oct 28;19(40):6834-41. doi: 10.3748/wjg.v19.i40.6834.

14.

Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.

Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM.

J Hepatol. 2014 Jun;60(6):1127-34. doi: 10.1016/j.jhep.2014.02.013. Epub 2014 Feb 26.

PMID:
24583247
15.

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.

Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

Hepatology. 2013 Jul;58(1):98-107. doi: 10.1002/hep.26180. Epub 2013 Mar 6.

PMID:
23213040
16.

Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.

Maklad S, Doss W, El Din SS, Hassan K, Zeid AA.

Arab J Gastroenterol. 2014 Mar;15(1):1-5. doi: 10.1016/j.ajg.2014.01.003. Epub 2014 Feb 4.

PMID:
24630505
17.

Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.

Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY, Hyun JJ, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH.

Liver Int. 2015 Mar;35(3):860-9. doi: 10.1111/liv.12605. Epub 2014 Jul 5.

PMID:
24905912
18.

Clinical study on prevention of HBV re-infection by entecavir after liver transplantation.

Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH.

Clin Transplant. 2012 Mar-Apr;26(2):208-15. doi: 10.1111/j.1399-0012.2011.01448.x. Epub 2011 Oct 10.

PMID:
21981656
19.

Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance.

Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH, Lee HS, Kim YJ.

Antimicrob Agents Chemother. 2014;58(3):1730-7. doi: 10.1128/AAC.02483-13. Epub 2014 Jan 6.

Supplemental Content

Support Center